Advertisement

Drugs

, Volume 67, Issue 5, pp 669–683 | Cite as

Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN®) in Focal Dystonia

  • Wolfgang H. JostEmail author
  • Jörg Blümel
  • Susanne Grafe
Leading Article

Abstract

Botulinum neurotoxin type A (BTX-A) weakens voluntary muscle strength and is an effective therapy for focal dystonia, including cervical dystonia (CD) and benign essential blepharospasm (BEB). It is also known to relieve hemifacial spasm and focal spasticity in children and adults. In addition, BTX-A has been shown to be effective in a wide range of other indications, such as gastrointestinal disorders, hyperhidrosis and cosmetic wrinkle correction (e.g. glabellar frown lines). A new formulation of BTX-A, NT 201 (XEOMIN®) has been developed. NT 201 is a formulation of pure BTX-A free of complexing proteins and, therefore, may have a reduced immunogenic potential compared with other BTX-A preparations. The pre-clinical and clinical development of NT 201 is reviewed in this article.

A total of five clinical trials were completed in Europe and Israel. Two studies were conducted in 46 healthy volunteers. A further three studies in 816 patients were conducted to provide data on the safety and efficacy of NT 201 in the treatment of CD and BEB. NT 201 was found to provide non-inferior efficacy and safety profiles in the treatment of CD and BEB compared with a BTX-A preparation containing complexing proteins (BOT [BOTOX®]). The clinical development programme of NT 201 showed a 1 : 1 NT 201 to BOT dose ratio. The pre-clinical studies conducted with NT 201 showed an acceptable safety profile and support the use of NT 201 in an intramuscular administration regimen for patients with CD and BEB. NT 201 was effective, well tolerated and non-inferior to BOT in the treatment of both CD and BEB. In addition, there were no differences between the two therapies in terms of onset of action, duration and waning of effect. Further research is required to determine the long-term efficacy and safety profile of NT 201.

Keywords

Cervical Dystonia Compound Muscle Action Potential Hemifacial Spasm Focal Dystonia Spasmodic Torticollis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The authors would like to thank Georg Comes for excellent biometrical advice. Drs Blümel and Grafe are full time employees of Merz Pharmaceuticals which sponsored all the studies discussed in this manuscript and is the Market Authorization Holder for NT 201 in Germany.

References

  1. 1.
    Costa J, Espirito-Santo C, Borges A, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 2005; (1): CD003633Google Scholar
  2. 2.
    Costa J, Espirito-Santo C, Borges A, et al. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev 2004; (2): CD004900Google Scholar
  3. 3.
    Tsui JK, Bhatt M, Calne S, et al. Botulinum toxin in the treatment of writer’s cramp: a double-blind study. Neurology 1993; 43 (1): 183–5PubMedCrossRefGoogle Scholar
  4. 4.
    Mall V, Heinen F, Siebel A, et al. Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study. Dev Med Child Neurol 2006 Jan; 48 (1): 10–3PubMedCrossRefGoogle Scholar
  5. 5.
    Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl Med J 2002 Aug; 347 (6): 395–400CrossRefGoogle Scholar
  6. 6.
    Brisinda G, Maria G, Bentivoglio AR, et al. The role of botulinum toxin in gastrointestinal disorders. In: Brin MF, Hallett M, Jankovic J, editors. Scientific and therapeutic aspects of Botulinum toxin. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 269–85Google Scholar
  7. 7.
    Naumann M. Evidence-based medicine: botulinum toxin in focal hyperhidrosis. J Neurol 2001 Apr; 248 (1): 131–3CrossRefGoogle Scholar
  8. 8.
    Carruthers J, Fagien S, Matarasso SL. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg 2004 Nov; 114 (6): 1–22Google Scholar
  9. 9.
    Cather JC, Menter A. Update on botulinum toxin for facial aesthetics. Dermatol Clin 2002 Oct; 20 (4): 749–61PubMedCrossRefGoogle Scholar
  10. 10.
    Butler AG, Duffey PO, Hawthorne MR, et al. An epidemiologic survey of dystonia within the entire population of northeast England over the past nine years. Adv Neurol 2004; 94: 95–9PubMedGoogle Scholar
  11. 11.
    Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord 2004 Mar; 19 (8): S109–15PubMedCrossRefGoogle Scholar
  12. 12.
    King Ching Tsui J. Blepharospasm and hemifacial spasm. In: Brin MF, Comella C, Jankovic J, editors. Dystonia: etiology, clinical features, and treatment. Philadelphia (PA): Lippincott Willimas & Wilkins, 2004: 151–7Google Scholar
  13. 13.
    Berardelli A, Kaji R, Currà A. Physiology of dystonia. In: Brin MF, Comella C, Jankovic J, editors. Dystonia: etiology, clinical features, and treatment. Philadelphia (PA): Lippincott Williams & Wilkins, 2004: 33–7Google Scholar
  14. 14.
    Hallett M. Blepharospasm: recent advances. Neurology 2002 Nov; 59 (9): 1306–12PubMedCrossRefGoogle Scholar
  15. 15.
    Kessler KR, Benecke R. Botulinum toxin: from poison to remedy. Neurotoxicology 1997; 18 (3): 761–70PubMedGoogle Scholar
  16. 16.
    De Paiva A, Meunier FA, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 1999 Mar; 96 (6): 3200–5PubMedCrossRefGoogle Scholar
  17. 17.
    Lee JC, Yokota K, Arimitsu H, et al. Production of antineurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxinhaemagglutinin. Microbiology 2005 Nov; 151 (Pt 11): 3739–47PubMedCrossRefGoogle Scholar
  18. 18.
    Blümel J, Frevert J, Schwaier A. Comparative antigenicity of three preparations of botulinum neurotoxin type A in the rabbit [abstract]. Neurotox Res 2006; 9 (2): 238Google Scholar
  19. 19.
    Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003 Apr; 60 (7): 1186–8PubMedCrossRefGoogle Scholar
  20. 20.
    Jost WH, Kohl A, Brinkmann S, et al. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT201) compared with commercially available botulinum toxin type A (BOTOX®) in healthy volunteers. J Neural Transm 2005; 112 (7): 905–13PubMedCrossRefGoogle Scholar
  21. 21.
    Wohlfarth K, Mueller C. Safety, efficacy, and duration of effect of a new botulinum neurotoxin type A preparation free of complexing proteins [abstract]. Mov Disord 2005; 20 (10): S11Google Scholar
  22. 22.
    Wohlfarth K, Müller C, Sassin I, et al. No spread of a new botulinum neurotoxin type A preparation in adjacent muscles. Neurotox Res 2006; 9 (2): 236Google Scholar
  23. 23.
    Benecke R, Jost W, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005; 64: 1949–51PubMedCrossRefGoogle Scholar
  24. 24.
    Roggenkämper P, Jost WH, Bihari K, et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006 Mar; 113 (3): 303–12PubMedCrossRefGoogle Scholar
  25. 25.
    Merz Pharmaceuticals GmbH. Summary of product characteristics Xeomin®. Frankfurt: Merz Pharmaceuticals GmbH, 2006 MarGoogle Scholar
  26. 26.
    Schantz EJ, Kautter DA. Microbiological methods: standardized assay for Clostridium botulinum neurotoxins. J Assoc Off Anal Chem 1978; 61 (1): 96–9Google Scholar
  27. 27.
    Merz Pharmaceuticals GmbH. Oral toxicity of NT-101 in CD-1 mice. Frankfurt: Merz Pharmaceuticals GmbH, 2000. LPT Report No. 12798/99, study reportGoogle Scholar
  28. 28.
    Fujinaga Y, Inoue K, Nomura T, et al. Identification and characterization of functional subunits of Clostridium botulinum type A progenitor neurotoxin involved in binding to intestinal microvilli and erythrocytes. FEBS Lett 2000 Feb; 467 (2–3): 179–83PubMedCrossRefGoogle Scholar
  29. 29.
    Sharma SK, Singh BR. Hemagglutinin binding mediated protection of botulinum neurotoxin from proteolysis. J Nat Neurotoxins 1998; 7 (3): 239–53Google Scholar
  30. 30.
    Merz Pharmaceuticals GmbH. Comparative systemic toxicity of NT-201 in mice following intravenous administration. Frankfurt: Merz Pharmaceuticals GmbH, 1998. LPT Report No. 11252/1/98 + Addendum, study reportGoogle Scholar
  31. 31.
    Merz Pharmaceuticals GmbH. NT 201–13 week toxicity study with repeated intramuscular administrations in the cynomolgus monkey. Frankfurt: Merz Pharmaceuticals GmbH, 2004. Study Number 442/016, study reportGoogle Scholar
  32. 32.
    Milano S, Chalencon E, Lege P, et al. Telemetry as a tool to evaluate simultaneously the efficacy and safety of a neuromuscular blocking agent in the monkey [abstract]. J Pharmacol Toxicol Methods 2005; 52 (1): 202Google Scholar
  33. 33.
    Göschel H, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies — therapeutic consequences. Exp Neurol 1997; 147 (1): 96–102PubMedCrossRefGoogle Scholar
  34. 34.
    Buchman AS, Comella CL, Stebbins GT, et al. Determining a dose-effect curve for botulinum toxin in the sternocleidomastoid muscle in cervical dystonia. Clin Neuropharmacol 1994; 17 (2): 188–95CrossRefGoogle Scholar
  35. 35.
    Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker, 1994: 211–37Google Scholar
  36. 36.
    Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987; 37 (4): 616–23PubMedCrossRefGoogle Scholar
  37. 37.
    Goertelmeyer R, Brinkmann S, Comes G, et al. The Blepharospasm Disability Index (BSDI) for the assessment of functional health in focal dystonia. Clin Neurophysiol 2002; 113 (1): S77–8Google Scholar
  38. 38.
    Görtelmeyer R, Grafe S, Comes G. The Blepharospasm Disability Index (BSDI): reliability and validity. Neurotox Res 2006; 9 (2): 237Google Scholar
  39. 39.
    Epidemiologic Study of Dystonia in Europe. Sex-related influences on the frequency and age of onset of primary dystonia. Neurology 1999 Nov; 53 (8): 1871–3CrossRefGoogle Scholar
  40. 40.
    Anderson RL, Patel BC, Holds JB, et al. Blepharospasm: past, present, and future. Ophthal Plast Reconstr Surg 1998 Sep; 14 (5): 305–17PubMedCrossRefGoogle Scholar
  41. 41.
    Santos JI, Swensen P, Glasgow LA. Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics 1981; 68 (1): 50–4PubMedGoogle Scholar
  42. 42.
    Wang YC, Burr DH, Korthals GJ, et al. Acute toxicity of aminoglycoside antibiotics as an aid in detecting botulism. Appl Environ Microbiol 1984 Nov; 48 (5): 951–5PubMedGoogle Scholar
  43. 43.
    Yamada S, Kuno Y, Iwanaga H. Effects of aminoglycoside antibiotics on the neuromuscular junction: part I. Int J Clin Pharmacol Ther Toxicol 1986; 24 (3): 130–8PubMedGoogle Scholar
  44. 44.
    Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol 2000 Aug; 43 (2): 249–59PubMedCrossRefGoogle Scholar
  45. 45.
    Simpson LL. The interaction between aminoquinolines and presynaptically acting neurotoxins. J Pharmacol Exp Ther 1982 Jul; 222 (1): 43–8PubMedGoogle Scholar
  46. 46.
    Walts LF. Neuromuscular blocking drugs. Otolaryngol Clin North Am 1981 Aug; 14 (3): 501–13PubMedGoogle Scholar
  47. 47.
    Brashear A, Watts MW, Marchetti A, et al. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review. Clin Ther 2000 Dec; 22 (12): 1516–24PubMedCrossRefGoogle Scholar
  48. 48.
    Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005 Nov; 65 (9): 1423–9PubMedCrossRefGoogle Scholar
  49. 49.
    Defazio G, Livrea P. Primary blepharospasm: diagnosis and management. Drugs 2004; 64 (3): 237–44PubMedCrossRefGoogle Scholar
  50. 50.
    Jankovic J. Treatment of cervical dystonia. In: Brin MF, Comella C, Jankovic J, editors. Dystonia: etiology, clinical features, and treatment. Philadelphia (PA): Lippincott Williams & Wilkins, 2004: 159–66Google Scholar
  51. 51.
    Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Res 2006; 9 (2): 145–8PubMedCrossRefGoogle Scholar
  52. 52.
    Borodic G, Johnson E, Goodnough M, et al. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1996; 46 (1): 26–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Wolfgang H. Jost
    • 1
    Email author
  • Jörg Blümel
    • 2
  • Susanne Grafe
    • 2
  1. 1.Department of Neurology and Clinical NeurophysiologyDeutsche Klinik für DiagnostikWiesbadenGermany
  2. 2.Merz Pharmaceuticals GmbHFrankfurtGermany

Personalised recommendations